Skip to main content
Premium Trial:

Request an Annual Quote

Admera Health Inks Deals to Expand Presence in Asia

NEW YORK (GenomeWeb) – Molecular diagnostics firm Admera Health announced today that it has signed three deals that will expand the availability of its pharmacogenomics tests in Asia.

Under the first deal, Admera will gain access to the existing physician network of Angsana Molecular & Diagnostics Laboratory, a molecular diagnostic assay developer with offices in Singapore, Hong Kong, and Malaysia. Under the other two deals, South Korea-based Biois and Taiwan-based AllBio Pharma will distribute Admera's full product portfolio.

Additional terms were not disclosed.

"These partnerships align with our strategic goals of expanding our global footprint and making pharmacogenomics standard of care globally," Brady Millican, vice president of business development at Admera, said in a statement. "We are especially excited about our new partners' interests in deploying pharmacogenomics within cardiovascular and oncology clinics."

Admera currently offers PGxOne Plus, a next-generation sequencing-based test that interrogates 50 genes with coverage of roughly 200 genetic variants to predict how patients will respond to drug therapy. The company also sells tests for tumor profiling and cardiovascular disease.